VIVO - メリディアン・バイオサイエンス (Meridian Bioscience Inc.)

VIVOのニュース

   Latin American Dedicated Internet Access (DIA) Services Market Report 2022: Developing and/or Strengthening Telcos'' Managed Services Portfolio to present Future Opportunities - ResearchAndMarkets.com  2022/12/19 10:34:00 Kwhen Finance
   Meridian Biosciences Stock: Why I Moved On But May Go Back In (NASDAQ:VIVO)  2022/12/13 19:53:57 Seeking Alpha
Meridian Biosciences released an update saying it set the closing date for its merger on Jan. 31. Read more on this deal and implications for investors.
   Meridian Bioscience stock gains after announcing Jan. 31 closing date for sale  2022/12/12 15:54:02 Seeking Alpha
Meridian Bioscience (VIVO) rose 8% after it said its planned sale to SD Biosensor, SJL Partners is expected to close on Jan
   Meridian Bioscience Fiscal Q4 Revenues Fall 14 Percent, Full-Year Revenues Grow 5 Percent  2022/11/22 15:14:01 GenomeWeb
The firm''s diagnostics segment revenues climbed 14 percent year over year in fiscal Q4, while life sciences revenues were down 37 percent.
   Meridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67M  2022/11/22 13:46:35 Seeking Alpha
Meridian Bioscience press release (VIVO): Q4 Non-GAAP EPS of $0.21.Revenue of $65.67M (-13.8% Y/Y).Diagnostics segment net revenues increased 14% year-over-year to $39.2…
   Looking Into Meridian Bioscience''s Return On Capital Employed  2022/08/26 14:33:47 Benzinga
Meridian Bioscience (NASDAQ: VIVO ) brought in sales totaling $67.77 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 125.52%, resulting in a loss of $7.34 million. In Q2, Meridian Bioscience earned $28.75 million and total sales reached $111.23 million. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
   Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M (NASDAQ:VIVO)  2022/08/05 12:47:57 Seeking Alpha
Meridian Bioscience press release (VIVO): Q3 Non-GAAP EPS of $0.16 misses by $0.01.Revenue of $67.8M (+6.8% Y/Y) beats by $1M.Due to the pending transaction, Meridian will no…
   Meridian Bioscience: Q3 Earnings Insights  2022/08/05 12:30:51 Benzinga
Meridian Bioscience (NASDAQ: VIVO ) reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Meridian Bioscience reported in-line EPS of $0.16 versus an estimate of $0.16. Revenue … Full story available on Benzinga.com
   Meridian Bioscience Misses Q3 EPS by 1c By Investing.com  2022/08/05 12:15:01 Investing.com
Meridian Bioscience Misses Q3 EPS by 1c
   MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS  2022/08/05 12:00:00 PR Newswire
CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million,…
   Meridian Bioscience rises 5% on boosted fiscal 2022 guidance  2022/02/04 17:13:47 Seeking Alpha
Meridian Bioscience <> rose following its Q1 results and a raised fiscal 2022 guidance.The company said net revenues in Q1 fiscal were $88.3M, only 5% below the record $92.9M in
   Meridian Bioscience Q1 2022 Earnings Preview  2022/02/03 18:20:27 Seeking Alpha
Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is $0.27 (-52.6% Y/Y) and the
   GTS Sells SP5 Portfolio Company Comprising 2,115 Towers  2022/02/01 22:59:00 Kwhen Finance
   Meridian awarded additional NIH funding to advance development of Revogene panel  2022/01/31 17:12:53 Seeking Alpha
Meridian Bioscience <> announced that the National Institute of Health ((NIH)) awarded an additional $2.5M worth of funding to accelerate the development of its Revogene
   Meridian Bioscience launches saliva-specific mixes for DNA, RNA detection  2022/01/28 15:19:47 Seeking Alpha
Meridian Bioscience <> launched two master mixes that detect DNA and RNA in crude saliva samples.The company said the two new mixes, Lyo-Ready Direct DNA qPCR Saliva Mix…

calendar